Harmony Biosciences (HRMY) Competitors $34.28 +0.39 (+1.15%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HRMY vs. LNTH, NUVL, LEGN, BPMC, ELAN, CYTK, TGTX, VKTX, BBIO, and CRNXShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Lantheus Nuvalent Legend Biotech Blueprint Medicines Elanco Animal Health Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Lantheus (NASDAQ:LNTH) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Do institutionals and insiders hold more shares of LNTH or HRMY? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer LNTH or HRMY? In the previous week, Lantheus had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 13 mentions for Lantheus and 12 mentions for Harmony Biosciences. Lantheus' average media sentiment score of 0.85 beat Harmony Biosciences' score of 0.84 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate LNTH or HRMY? Lantheus presently has a consensus target price of $131.86, indicating a potential upside of 47.67%. Harmony Biosciences has a consensus target price of $49.80, indicating a potential upside of 45.27%. Given Lantheus' stronger consensus rating and higher possible upside, research analysts clearly believe Lantheus is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Harmony Biosciences 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is LNTH or HRMY more profitable? Lantheus has a net margin of 28.57% compared to Harmony Biosciences' net margin of 17.98%. Lantheus' return on equity of 44.29% beat Harmony Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus28.57% 44.29% 23.52% Harmony Biosciences 17.98%23.16%14.24% Which has more risk & volatility, LNTH or HRMY? Lantheus has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Which has higher valuation & earnings, LNTH or HRMY? Lantheus has higher revenue and earnings than Harmony Biosciences. Lantheus is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.50B4.15$326.66M$6.0114.86Harmony Biosciences$681.88M2.87$128.85M$2.1116.25 Does the MarketBeat Community favor LNTH or HRMY? Lantheus received 285 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 66.67% of users gave Harmony Biosciences an outperform vote while only 65.83% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformLantheusOutperform Votes33965.83% Underperform Votes17634.17% Harmony BiosciencesOutperform Votes5466.67% Underperform Votes2733.33% SummaryLantheus beats Harmony Biosciences on 13 of the 18 factors compared between the two stocks. Ad True Market InsidersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024>3-Cent Amazon Coin< Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio16.2510.5991.3417.19Price / Sales2.87195.381,116.59116.80Price / Cash12.3857.1642.6437.86Price / Book4.305.104.794.78Net Income$128.85M$151.51M$120.07M$225.60M7 Day Performance5.84%-2.15%-1.89%-1.24%1 Month Performance3.16%-3.14%11.45%3.36%1 Year Performance6.16%11.50%30.61%16.58% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.783 of 5 stars$34.28+1.2%$49.80+45.3%+7.0%$1.96B$681.88M16.25200Analyst ForecastAnalyst RevisionHigh Trading VolumeLNTHLantheus4.3807 of 5 stars$94.38+1.5%$130.00+37.7%+53.4%$6.56B$1.50B15.42834Analyst ForecastNUVLNuvalent2.1944 of 5 stars$86.53-0.4%$112.60+30.1%+16.9%$6.15BN/A-25.0340Insider TradeNews CoveragePositive NewsLEGNLegend Biotech1.5523 of 5 stars$33.61-4.3%$81.54+142.6%-43.2%$6.14B$520.18M-36.971,800BPMCBlueprint Medicines2.5701 of 5 stars$95.23+2.2%$122.11+28.2%+7.2%$6.05B$434.42M-45.28640Insider TradeELANElanco Animal Health3.7792 of 5 stars$12.20+0.8%$16.75+37.3%-17.0%$6.03B$4.45B30.259,300CYTKCytokinetics4.1408 of 5 stars$49.20+1.1%$83.93+70.6%+36.8%$5.81B$3.22M-9.04250Analyst ForecastTGTXTG Therapeutics4.3127 of 5 stars$34.81+8.7%$40.67+16.8%+87.1%$5.42B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2931 of 5 stars$48.10+2.3%$106.75+121.9%+139.8%$5.36BN/A-51.5620Analyst ForecastGap UpBBIOBridgeBio Pharma4.6974 of 5 stars$27.67+0.7%$47.69+72.4%-30.7%$5.23B$217.77M-11.63400CRNXCrinetics Pharmaceuticals4.0778 of 5 stars$54.15+0.9%$70.82+30.8%+55.4%$5.02B$1.04M-14.39210Positive News Related Companies and Tools Related Companies Lantheus Alternatives Nuvalent Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives TG Therapeutics Alternatives Viking Therapeutics Alternatives BridgeBio Pharma Alternatives Crinetics Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HRMY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
